Alpha-2-antiplasmin in acute nonlymphoblastic leukemia

E. Cofrancesco, E. Pogliani, M. Salvatore, G. Moreo, C. Boschetti, M. Cortellaro

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The levels of alpha-2-antiplasmin (α2-AP), antithrombin III (At III) and plasminogen were studied in 21 patients with acute nonlymphoblastic leukemia (ANLL) before and after induction chemotherapy and during bone marrow cellularity recovery after the postchemotherapy aplastic phase. In the patients with M2, M3 or M4 leukemia who had clinical and laboratory evidence of DIC, the α2-AP levels were very low in the initial phase of the disease but improved significantly during recovery of marrow cellularity. At III and plasminogen values were in the normal range at disease onset and showed no significant modification during the course of leukemia. Proteolytic cleavage of α2-AP by granulocyte proteases, rather than hyperfibrinolysis, may be responsible for the low levels of the inhibitor in the proliferative phase of ANLL. This α2-AP deficiency may well contribute to hemorrhagic diathesis in ANLL independently of the presence or absence of hyperfibrinolysis or DIC. Moreover, the lower α2-AP levels observed during the proliferative phase of ANLL may relate to disease activity.

Original languageEnglish
Pages (from-to)122-125
Number of pages4
JournalActa Haematologica
Volume81
Issue number3
Publication statusPublished - 1989

Fingerprint

alpha-2-Antiplasmin
Acute Myeloid Leukemia
Antifibrinolytic Agents
Dacarbazine
Antithrombin III
Plasminogen
Leukemia
Bone Marrow
Hemorrhagic Disorders
Induction Chemotherapy
Granulocytes
Reference Values
Peptide Hydrolases

ASJC Scopus subject areas

  • Hematology

Cite this

Cofrancesco, E., Pogliani, E., Salvatore, M., Moreo, G., Boschetti, C., & Cortellaro, M. (1989). Alpha-2-antiplasmin in acute nonlymphoblastic leukemia. Acta Haematologica, 81(3), 122-125.

Alpha-2-antiplasmin in acute nonlymphoblastic leukemia. / Cofrancesco, E.; Pogliani, E.; Salvatore, M.; Moreo, G.; Boschetti, C.; Cortellaro, M.

In: Acta Haematologica, Vol. 81, No. 3, 1989, p. 122-125.

Research output: Contribution to journalArticle

Cofrancesco, E, Pogliani, E, Salvatore, M, Moreo, G, Boschetti, C & Cortellaro, M 1989, 'Alpha-2-antiplasmin in acute nonlymphoblastic leukemia', Acta Haematologica, vol. 81, no. 3, pp. 122-125.
Cofrancesco E, Pogliani E, Salvatore M, Moreo G, Boschetti C, Cortellaro M. Alpha-2-antiplasmin in acute nonlymphoblastic leukemia. Acta Haematologica. 1989;81(3):122-125.
Cofrancesco, E. ; Pogliani, E. ; Salvatore, M. ; Moreo, G. ; Boschetti, C. ; Cortellaro, M. / Alpha-2-antiplasmin in acute nonlymphoblastic leukemia. In: Acta Haematologica. 1989 ; Vol. 81, No. 3. pp. 122-125.
@article{f4b67da98122490faed00ded8934c362,
title = "Alpha-2-antiplasmin in acute nonlymphoblastic leukemia",
abstract = "The levels of alpha-2-antiplasmin (α2-AP), antithrombin III (At III) and plasminogen were studied in 21 patients with acute nonlymphoblastic leukemia (ANLL) before and after induction chemotherapy and during bone marrow cellularity recovery after the postchemotherapy aplastic phase. In the patients with M2, M3 or M4 leukemia who had clinical and laboratory evidence of DIC, the α2-AP levels were very low in the initial phase of the disease but improved significantly during recovery of marrow cellularity. At III and plasminogen values were in the normal range at disease onset and showed no significant modification during the course of leukemia. Proteolytic cleavage of α2-AP by granulocyte proteases, rather than hyperfibrinolysis, may be responsible for the low levels of the inhibitor in the proliferative phase of ANLL. This α2-AP deficiency may well contribute to hemorrhagic diathesis in ANLL independently of the presence or absence of hyperfibrinolysis or DIC. Moreover, the lower α2-AP levels observed during the proliferative phase of ANLL may relate to disease activity.",
author = "E. Cofrancesco and E. Pogliani and M. Salvatore and G. Moreo and C. Boschetti and M. Cortellaro",
year = "1989",
language = "English",
volume = "81",
pages = "122--125",
journal = "Acta Haematologica",
issn = "0001-5792",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Alpha-2-antiplasmin in acute nonlymphoblastic leukemia

AU - Cofrancesco, E.

AU - Pogliani, E.

AU - Salvatore, M.

AU - Moreo, G.

AU - Boschetti, C.

AU - Cortellaro, M.

PY - 1989

Y1 - 1989

N2 - The levels of alpha-2-antiplasmin (α2-AP), antithrombin III (At III) and plasminogen were studied in 21 patients with acute nonlymphoblastic leukemia (ANLL) before and after induction chemotherapy and during bone marrow cellularity recovery after the postchemotherapy aplastic phase. In the patients with M2, M3 or M4 leukemia who had clinical and laboratory evidence of DIC, the α2-AP levels were very low in the initial phase of the disease but improved significantly during recovery of marrow cellularity. At III and plasminogen values were in the normal range at disease onset and showed no significant modification during the course of leukemia. Proteolytic cleavage of α2-AP by granulocyte proteases, rather than hyperfibrinolysis, may be responsible for the low levels of the inhibitor in the proliferative phase of ANLL. This α2-AP deficiency may well contribute to hemorrhagic diathesis in ANLL independently of the presence or absence of hyperfibrinolysis or DIC. Moreover, the lower α2-AP levels observed during the proliferative phase of ANLL may relate to disease activity.

AB - The levels of alpha-2-antiplasmin (α2-AP), antithrombin III (At III) and plasminogen were studied in 21 patients with acute nonlymphoblastic leukemia (ANLL) before and after induction chemotherapy and during bone marrow cellularity recovery after the postchemotherapy aplastic phase. In the patients with M2, M3 or M4 leukemia who had clinical and laboratory evidence of DIC, the α2-AP levels were very low in the initial phase of the disease but improved significantly during recovery of marrow cellularity. At III and plasminogen values were in the normal range at disease onset and showed no significant modification during the course of leukemia. Proteolytic cleavage of α2-AP by granulocyte proteases, rather than hyperfibrinolysis, may be responsible for the low levels of the inhibitor in the proliferative phase of ANLL. This α2-AP deficiency may well contribute to hemorrhagic diathesis in ANLL independently of the presence or absence of hyperfibrinolysis or DIC. Moreover, the lower α2-AP levels observed during the proliferative phase of ANLL may relate to disease activity.

UR - http://www.scopus.com/inward/record.url?scp=0024601070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024601070&partnerID=8YFLogxK

M3 - Article

C2 - 2469277

AN - SCOPUS:0024601070

VL - 81

SP - 122

EP - 125

JO - Acta Haematologica

JF - Acta Haematologica

SN - 0001-5792

IS - 3

ER -